biswell2
10 May 2016
Excellent Trading Update If there are any potential predators looking at Cyprotex this update will one imagine not drive them awayAny strategic partner hovering about being such might not hover before landing a strategic deal10 May 2016Cyprotex PLCTrading Update Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first quarter of 2016. The financial performance of the Company for the first quarter of the year is significantly ahead of the Boards' expectations, comparative period performance and internal budgets. The Board also confirms that the Company's strategic review is progressing.
Carefully Does It
09 May 2016
Re: previous announcement Stategic review still ongoing I believe. Today was called to satisy market needs in these circumstances not to announce outcome of the review..
up protherics
09 May 2016
previous announcement Could someone verify that the board previously announced that no action was required.. As I understood their previuos announcement said that they were exploring all optionsTakeover/merger/strategic alliance/restructuring of debt..I may have missed something somewhere, but did they actually announce that they believed that no action was required at the time of this strategic revue announcement.
up protherics
09 May 2016
Meeting INMO.. The outcome was a good one. However it would have been ideal if they could have reduced the loan notes in some way.We just need the company to generate as much cash as possible over the next couple of years to repay the notes rather than dilute the share capital.
biswell2
22 Apr 2016
Re: Cyprotex mentioned with Multi US $Bi... The equipment purchased a year or so back is being put to good use it seemsIf only some of these assays could be IP protected then their creation would be worth $ MillionsA Combined in Vitro Approach to Improve the Prediction of Mitochondrial Toxicants – Mitochondrial stress testPosted 21st April 2016 by CyprotexA recent peer-reviewed publication in Toxicology in Vitro presents research by Cyprotex on methods to investigate drug- or chemical-induced mitochondrial toxicity.Mitochondrial toxicity is a potentially very serious side effect that can play a role in drug- or chemical-induced organ failure. Mitochondria are essential organelles that a responsible for creation of ATP and providing energy for vital cellular functions, so mitochondrial stress or damage can have a debilitating impact. There has also been growing interest in in vitro mitochondrial toxicity assessment during drug discovery and development because its implication in both attrition and market withdrawal is on the rise.The Glu/Gal assay is the current standard for evaluating mitochondrial risk by comparing the cytotoxicity of compounds in galactose media to glucose media. Because cells are more reliant on mitochondrial oxidative phosphorylation in galactose, they are also more sensitive to mitochondrial toxicants.However, a more recent approach, made possible using the Seahorse XFe96 Flux Analyser provides mitochondrial toxicity data in real time by measuring oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and reserve capacity.The publication explores if one approach is more predictive than the other, or if combining the two methods yields better results. The research concludes that the Seahorse assay was highly predictive and correctly identified 78% of the test compounds, all of which were known mitochondrial toxicants, compared to 41% identified by the Glu/Gal assay. However, the Glu/Gal assay did identify one compound that the Seahorse assay did not. combining the assays, sensitivity was increased to 81%, specificity was 100% and accuracy was 92%. The Seahorse assay was also able to correctly identify the mechanism in over 76% of cases.
up protherics
21 Apr 2016
Lets Hope Lets hope that this strategic review benefits PI investors in some way.Personally I will be looking for the followingA repayment of the loan notes in full or in part. If in part the repayment of the loan note. Which I have said all along was a ridiculous part of their fund raising requirements .The convertible seems more justifiable.A strategic partnership where existing shareholders are not dilutedAlternatively a buyout at a decent premium to todays price.. I.E at least 40% above current levels.AlsoDoes anyone have any ideas why we are continuously being bombarded by RNS 8.3 and 8.5.My understanding is that holders above 1% only have to notify the market once during an official offer period.
swisspaul
19 Apr 2016
Re: Cyprotex mentioned with Multi US $Billio... aaND THE RESEARCH WAS COMMISSIONED AND PAID BY WHOM?
biswell2
18 Apr 2016
Cyprotex mentioned with Multi US $Billion Co's 04-11-2016In Vitro Toxicity Testing Market to Reach US$4.1 bn by 2018 due to Rising Health-consciousnessTransparency Market Research (TMR) has recently published a research study on the global in-vitro toxicity testing market. The report estimates this market to rise at a CAGR of 15.30% over the period from 2012 to 2018 and reach US$4.1 bn by the end of the forecast period.The research report, titled “In Vitro Toxicity Testing Market - Global Industry Size, Share, Trends, Analysis And Forecast 2012 - 2018,” states that the worldwide market for in-vitro toxicity testing attained a value of US$1.5 bn in 2011.In-vitro toxicity testing is the scientific analysis of the impact of toxic chemical substances on mammalian cells or cultured bacteria, which is primarily utilized to identify harmful chemicals in agricultural products, therapeutic drugs, and food additives. According to the popular notion among various toxicologists, in-vitro toxicity testing methods are more useful, efficient, and less time-consuming compared to toxicology studies.The strong objection of environmentalists to animal testing has influenced the demand for in-vitro toxicity testing positively. Technical advancements in the in-vitro toxicity testing methods are also propelling this market significantly.The report studies the worldwide in-vitro toxicity testing market on the basis of the type of in-vitro toxicity testing and the regional spread of this market. Based on the regional spread of the worldwide in-vitro toxicity testing market has been segmented into Europe, Asia, North America, and the Rest of the World.North America led the overall market with a share of approximately 40% in 2010, attaining a value of US$526.9 mn. Analysts project this regional market to retain its leadership during the forecast period. However, Europe is likely to surpass North America in the long term, states the report.The growing prevalence of cosmetic product testing in Europe is expected to boost the in-vitro testing market in this region over the forthcoming years. In addition to this, the ban on animal testing in this region also fueling the demand for in-vitro testing for the analysis of genotoxic effects.Based on the type of in-vitro toxicity testing, the market has been classified on the basis of dose, absorption, and toxic substances. dose, the market has been segmented into dose response and threshold response. absorption, distribution, excretion, and metabolism have been identified as the key segments of this market. Toxic substances-wise, the report categorizes this market into acute and chronic toxicity, toxin, toxicant, and toxicokinetics.The study also evaluates the global in-vitro toxicity testing market on the basis of application and end user. In-vitro toxicity testing methods and cytotoxicity assays used for in-vitro toxicity testing have been identified as the main application segments of this market and the pharmaceutical industry, the food and beverages industry, the chemicals industry, and cosmetics and household products have been identified as the key end users of in-vitro toxicity testing.Covance Inc., Charles River Laboratories International Inc., Accelrys Inc., Cyprotex, and Bio-Rad Laboratories are the leading enterprises functioning in the global in-vitro toxicity testing market.Other prominent companies mentioned in this report are Xenobiotic Detection Systems (XDS), Gene Logic Inc., Mattek Corp., In Vitro Technologies, Molecular Toxicology Inc., RTI Health Solutions, MB Research Laboratories, SBW Ltd., and Xenometrix.Full Research Report on Global In-vitro Toxicity Testing Market:www.transparencymarketresearch.com/in-vitro-toxicity-test...
up protherics
10 Apr 2016
Nomad INMHO.. A new NOMAD is urgently required.. Preferably one that is non bias and not in any spivs pock
up protherics
10 Apr 2016
EGM Anyone interested in calling for a EGM.. Not sure what percent is required though, but If we do I am sure we could disrupt things a little and keep things on a level playing field.For the spivs out there that translates to zzzeezzzeeezzz zzzeee r ggg
up protherics
09 Apr 2016
Re: Cynicle I hope you are right..Personally what I would like to see is either the convertible or loan notes paid off early and the company remain independent.. A joint venture is fine in my opinion as it would still give them scope to develop their business in different directions.Surely there is some clause somewhere that under certain cicumstances the notes could be repaid early
Carefully Does It
08 Apr 2016
Re: Cynicle It will come out OK.No need to do anything.Sit and wait.
up protherics
08 Apr 2016
Cynicle Being cynical as I am.. Lets have a merger with ADVFN in that way all posters will benefit.Form 123z will be issued shortly
up protherics
07 Apr 2016
Trades According to the latest announcement R Sneller purchased 50,000. Does anyone know where the shares came from as far as i can see nothing has been reported through the exchangeTwo points here if its a private transfer then individuals are being approached to sell their holdings for whatever reasons. Why would you sell at this level if you believe the company is going to be taken over in some way. Unless you were led to believe that any merger/takeover would take the price lower. E.G loan notes.The other point is that if it is stake building by a number of individuals. Are they aware of something the rest of us is n
Carefully Does It
06 Apr 2016
Re: Shareprice pass, might be treasury shares?don't overthink this stuff.
